Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program

BACKGROUND: RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively lo...

Full description

Saved in:
Bibliographic Details
Main Authors: Carol, Hernan, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Billups, Catherine A., Geier, Brian, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3495996/
https://ncbi.nlm.nih.gov/pubmed/22753001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24235
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items